Current Treatment of Familial Hypercholesterolaemia
- 1 January 2014
- journal article
- review article
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 9 (2) , 76-81
Abstract
Familial hypercholesterolaemia is an autosomal-dominant disorder associated with mutations in the LDL receptor gene resulting in markedly elevated plasma low-density lipoprotein cholesterol levels. FH is significantly underrecognised with as many as 1 in 300 having the heterozygous form and 1 in 1 million having the homozygous form of the disease. Early diagnosis and treatment of FH is paramount to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of treatment is to reduce LDL-C by 50 % from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, LDL apheresis and in rare cases, liver transplantation. Pharmacologic treatment ranges from statin medications to newer agents such as lomitapide, mipomersin and PCSK9 inhibitors. Combination therapy is frequently required to achieve goal lipoprotein level reductions and prevent complications.Keywords
This publication has 66 references indexed in Scilit:
- The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult PatientsClinical Therapeutics, 2013
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering TherapyCirculation, 2011
- Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaJournal of Clinical Lipidology, 2011
- Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaJournal of Clinical Lipidology, 2011
- Molecular Basis of Autosomal Dominant HypercholesterolemiaCirculation, 2011
- Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately TreatedPLOS ONE, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Preemptive liver transplantation in a child with familial hypercholesterolemiaPediatric Transplantation, 2010
- Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment GoalPLOS ONE, 2010